Zecen Biotech Land $26 Million In Series C Financing

According to China Venture, Zecen Biotech just received around 26 million dollars in series C financing. This round of financing was led by Hongtai Capital, and followed by Wuxi Capital and few other intuitions. The funds will be used to increase the budget for research and development for its products and improve the technology platform.

Zecen Biotech was founded in 2011, it’s an in vitro diagnostic company that specializes in fully automated chemiluminescence products and operates POCT products. Zecen Biotech has launched a range of chemiluminescence products, including the high-throughput fully automated chemiluminometer CIA2800, small chemiluminometer POCT, biochemical analyzers and more.

At the end of 2019, a special variety of shell enzyme proteins developed by Zecen Biotech will be launched. The shell enzyme protein is a specific indicator of liver fibrosis and will bring good news to more than 100 million patients with liver disease. The company will keep bringing new products to the market.

Hongtai Capital is a private equity and venture capital firm that specializes in direct and fund of funds investments through Aplus Fund and Aplus Capital.

Wuxi Capital is a financial investment platform in China.